Please assess the completion status of the following clinical trial:

Trial Title: Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Post-menopausal women~* Asymptomatic microscopic hematuria (three or more red blood cells per high powered field on a single urine microscopy) in the absence of urinary tract infection.~Exclusion Criteria:~* Known urologic disease~* Presence of gross hematuria~* Presence of indwelling urologic foreign body (foley catheter, ureteral stent)~* Inability to obtain intravenous contrast CT scan (elevated creatinine, severe contrast allergy)~* History of pelvic irradiation or malignancy~* Not a candidate for vaginal estrogen~  * Allergy to vaginal estrogen~ * Current or prior diagnosis of breast or endometrial cancer~ * History of deep vein thrombosis/pulmonary embolus~ * Hypercoagulable state

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Premarin vaginal cream (Type: EXPERIMENTAL): Premarin vaginal cream to be applied intra-vaginally and to vulva as follows: 1 gram nightly for 2 weeks, followed by 0.5 gram twice weekly for 6 weeks.
- Placebo vaginal cream (Type: PLACEBO_COMPARATOR): Placebo vaginal cream to be applied intra-vaginally and to vulva as follows: 1 gram nightly for 2 weeks, followed by 0.5 gram twice weekly for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).